Johnson Chemical Pharmaceutical Works Co Ltd (4747) fair value: what the stock is really worth
As of Nov 10, 2026: fair value (intrinsic value) of Johnson Chemical Pharmaceutical Works Co Ltd stock TWD 6.34, price TWD 17.55, that is 63.9% below the price, quality 37 out of 100. Rating: strongly overvalued. Calculated from audited financials with 24 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.
How to read this chart
60‑month range 12.37 TWD – 55.00 TWD · fair‑value band 6.22 TWD – 7.03 TWD · the 17.55 TWD price screens above the 6.34 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.
Follow Johnson Chemical Pharmaceutical Works Co in your weekly email
Every Wednesday you see whether Johnson Chemical Pharmaceutical Works Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Johnson Chemical Pharmaceutical Works Co., Ltd. manufactures, imports, and sells pharmaceutical ingredients, materials and products in Taiwan. The company manufactures drugs in a variety of forms, such as solid dosage form, capsule, tablet, and powder and granule, as well as nasal spray forms.
Show moreShow less
It offers its products in various therapeutic areas, including central nervous system, respiratory, cardiovascular, gastrointestinal, endocrine system, vitamins, anti-inflammatory, cough and cold, pain reliever, etc. The company was founded in 1959 and is based in New Taipei City, Taiwan.
Stock analysis
Johnson Chemical Pharmaceutical Works Co Ltd (4747) currently trades at 17.55 TWD, while our model-based Fair Value estimate is 6.34 TWD, 64% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of 23.61 TWD per share, and 8 of the 24 models we run sit above the 17.55 TWD price.
Bear case: the Dividend Discount group reads lowest at 8.54 TWD, and 16 of the 24 models stay below the price. Data coverage for this calculation is low.
Scenario range: 6.22 TWD (bear) to 7.03 TWD (bull), the price of 17.55 TWD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 37/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Johnson Chemical Pharmaceutical Works Co Ltd reported revenue of 570M TWD in FY2025 versus 411M TWD in FY2021, a compound +8.5%/yr. Reported net income was 53.5M TWD in FY2025, compounding +2.2%/yr from FY2021.
Key figures
Market cap 1.6B TWD (≈ $48.6M) Micro · P/E ratio 18.1 · P/S ratio 2.76 · EPS (TTM) 0.9700 TWD · Dividend yield 3.0% · Net margin 15.5% · Return on equity 5.3% · Return on assets (EBIT) 5.5% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 39 out of 100 (low confidence).
What moves the price
The share trades about 45% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −64%, 4747 screens richer than that median.
Fair Value models
Bear6.22 TWDFair Value 6.34 TWDBull7.03 TWD
Price 17.55 TWD · Downside -63.9%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (0.3840 TWD per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF12.42 TWD12.69 TWD13.01 TWD82
Growth DCF12.43 TWD12.67 TWD12.93 TWD80
5Y EBITDA Exit17.00 TWD21.11 TWD25.82 TWD77
All 24 models by family
DCF Models
FCF DCF12.42 TWD12.69 TWD13.01 TWD82
5Y Revenue Exit15.62 TWD18.61 TWD22.42 TWD74
5Y EBITDA Exit17.00 TWD21.11 TWD25.82 TWD77
5Y P/E Exit16.49 TWD20.20 TWD23.98 TWD72
10Y Revenue Exit13.93 TWD15.97 TWD18.67 TWD68
10Y EBITDA Exit14.79 TWD17.38 TWD20.74 TWD70
10Y P/E Exit14.53 TWD16.86 TWD19.62 TWD65
Earnings-Based
Graham-Dodd4.00 TWD10.50 TWD13.70 TWD65
PEG = 1.02.01 TWD2.87 TWD3.73 TWD57
EPV15.74 TWD16.22 TWD16.60 TWD74
Dividend Discount
Gordon GGM5.72 TWD9.15 TWD11.78 TWD69
DDM Multi-Stage5.72 TWD7.92 TWD9.75 TWD67
Multiples
P/E Multiple9.71 TWD12.95 TWD16.18 TWD63
P/S Multiple7.50 TWD10.00 TWD12.51 TWD58
P/B Multiple62.77 TWD83.70 TWD104.62 TWD55
EV/EBIT21.79 TWD25.21 TWD28.63 TWD66
EV/EBITDA22.33 TWD25.93 TWD29.53 TWD67
EV/Revenue18.86 TWD22.00 TWD25.13 TWD54
Asset-Based
NCAV (Graham)7.79 TWD11.80 TWD14.75 TWD54
Growth DCF
Growth DCF12.43 TWD12.67 TWD12.93 TWD80
Rev-Margin DCF15.62 TWD18.56 TWD21.74 TWD74
Economic Profit
Residual Income11.41 TWD11.62 TWD12.17 TWD76
ROIC Compounder15.74 TWD16.22 TWD16.60 TWD72
Growth Earnings
Growth-Adj P/E7.56 TWD10.80 TWD14.05 TWD67
The fair value above starts from this blend and is adjusted for a stock split.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.50/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
−6.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.1%
Start year 2020 (pandemic). Over 10 years: +4.1% a year
Revenue growth 16 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.6%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in TWD ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis. Measured in TWD: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−5.5%
Earnings growth per share plus dividend.
Earnings per share, growth per year−8.5%
Dividend (yield on the price)3.0%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.18% → 13%
Growth Forecast
Little optimism in the price
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
less than -40 %
The company could shrink this much every year for the next five years and today's price would still be justified.
What forecasts expect
n/a
No analyst forecast available.
Calculated on free cash flow for fiscal year 2025. Over the last twelve months it was negative, so the figure above is uncertain.
Compare Johnson Chemical Pharmaceutical Works Co Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 605 stocks
Beats the industry median on 7/13 measures
A mixed picture versus its industry peers.
Valuation
Quality Score37 · Bottom 25%
Fair Value upside−63.9% · Bottom 25%
Profitability
Return on equity (12 months)5.3% · Below median
Return on assets2.6% · Below median
Net margin (12 months)15.5% · Top 25%
Operating margin (12 months)10.9% · Above median
Growth and dividend
Revenue growth (quarter YoY)6.0% · Above median
Dividend yield (12 months)3.0% · Above median
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Johnson Chemical Pharmaceutical Works Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/4747
Frequently asked questions
Is Johnson Chemical Pharmaceutical Works Co Ltd (4747) overvalued or undervalued?
As of Nov 10, 2026, our model estimates a fair value of 6.34 TWD versus a price of 17.55 TWD, about 64% lower (overvalued).
What is the fair value of 4747?
Our model-based fair value for Johnson Chemical Pharmaceutical Works Co Ltd is 6.34 TWD (as of Nov 10, 2026), built from audited fundamentals. The current price: 17.55 TWD.
What is the quality score of 4747?
Johnson Chemical Pharmaceutical Works Co Ltd has a Quality Score of 37/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Johnson Chemical Pharmaceutical Works Co Ltd (4747)?
Our model-based price target is the fair value of 6.34 TWD (as of Nov 10, 2026) from 24 valuation models. Cautious scenario 6.22 TWD, optimistic scenario 7.03 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the Johnson Chemical Pharmaceutical Works Co Ltd stock forecast for 2026?
Our models put fair value at 6.34 TWD, about 64% lower versus a price of 17.55 TWD (overvalued). Cautious scenario 6.22 TWD, optimistic scenario 7.03 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of Johnson Chemical Pharmaceutical Works Co Ltd (4747)?
Johnson Chemical Pharmaceutical Works Co Ltd reported trailing-twelve-month revenue of about 578M TWD (latest available figure, as of Nov 10, 2026).
Does Johnson Chemical Pharmaceutical Works Co Ltd pay a dividend?
Johnson Chemical Pharmaceutical Works Co Ltd currently shows a dividend yield of 2.99% relative to its recent price (as of Nov 10, 2026).
How much is the dividend of Johnson Chemical Pharmaceutical Works Co Ltd (4747) and when is the ex-dividend date?
Johnson Chemical Pharmaceutical Works Co Ltd pays a dividend of 0.525 TWD per share a year, a dividend yield of 3.0%. The last ex-dividend date was Jul 6, 2026. A dividend has been paid every year since at least 2012. The payout ratio is 54.1% of earnings. Free cash flow covers the dividend 0.16 times. Our assessment: Watch coverage. The dividend isn’t fully covered by free cash flow or earnings, part of it is funded from reserves or debt. Fine for now, but worth watching: if it stays uncovered, the dividend could be cut.
What growth is priced into Johnson Chemical Pharmaceutical Works Co Ltd (4747)?
For today's price to be fair in a discounted-cash-flow model, Johnson Chemical Pharmaceutical Works Co Ltd would have to grow free cash flow by less than minus 40 % per year for five years (discount rate 13.3 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +6.1 % per year. Calculated on free cash flow for fiscal year 2025. Over the last twelve months it was negative, so the figure above is uncertain. As of Nov 10, 2026.
What discount rate (WACC) does the fair value of 4747 use?
Our models discount Johnson Chemical Pharmaceutical Works Co Ltd at 13.3 %: a base by market capitalisation (micro), country premium for Taiwan. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Johnson Chemical Pharmaceutical Works Co Ltd that is less than minus 40 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (13.3 %) and the same formula as our fair value.
How much growth has Johnson Chemical Pharmaceutical Works Co Ltd (4747) delivered so far?
Over the past 5 years revenue at Johnson Chemical Pharmaceutical Works Co Ltd grew +6.1 % a year. The price currently implies free-cash-flow growth of less than minus 40 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Johnson Chemical Pharmaceutical Works Co Ltd (4747) growing?
The median revenue growth in the sector is +5.9 % a year. That is the yardstick for the growth priced into Johnson Chemical Pharmaceutical Works Co Ltd (less than minus 40 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Johnson Chemical Pharmaceutical Works Co Ltd (4747)?
The free-cash-flow yield on the price is 0.96 % in the last fiscal year (free cash flow was negative over the last twelve months): that much free cash flow Johnson Chemical Pharmaceutical Works Co Ltd produces per unit of market value. When it exceeds the discount rate of our models (13.3 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Johnson Chemical Pharmaceutical Works Co Ltd (4747)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Johnson Chemical Pharmaceutical Works Co Ltd it is 6.34 TWD per share (as of Nov 10, 2026), against a price of 17.55 TWD. It is the blended result of 24 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Johnson Chemical Pharmaceutical Works Co Ltd stock overvalued or undervalued in 2026?
As of Nov 10, 2026, 4747 trades above its calculated fair value: price 17.55 TWD, fair value 6.34 TWD, a gap of about −64% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 4747?
No. The price is what the market pays today (17.55 TWD); the fair value is what the company's own numbers justify (6.34 TWD). For Johnson Chemical Pharmaceutical Works Co Ltd the two are 11.22 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Johnson Chemical Pharmaceutical Works Co Ltd worth?
The market values Johnson Chemical Pharmaceutical Works Co Ltd at about 1.6B TWD (market capitalisation, as of Nov 10, 2026). Per share that is 17.55 TWD; our models calculate a fair value of 6.34 TWD per share.
What do the bullish and bearish scenarios say about 4747?
Our models span a range for Johnson Chemical Pharmaceutical Works Co Ltd: cautious scenario 6.22 TWD, base 6.34 TWD, optimistic 7.03 TWD per share (as of Nov 10, 2026, price 17.55 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 4747?
Johnson Chemical Pharmaceutical Works Co Ltd trades at a price-to-earnings ratio of 18.1 (as of Nov 10, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 6.34 TWD is built from several models across several years. Other multiples: P/B 0.9, P/S 2.8, EV/EBITDA 6.9.
How solid is the balance sheet of Johnson Chemical Pharmaceutical Works Co Ltd (4747)?
Balance-sheet figures for Johnson Chemical Pharmaceutical Works Co Ltd (as of Nov 10, 2026): return on equity 5.3%. They feed the Quality Score of 37/100, which measures business quality independently of the share price.
How far is 4747 from its 52-week high?
Johnson Chemical Pharmaceutical Works Co Ltd trades at 17.55 TWD, about 45% below its 52-week high of 31.85 TWD and at the low of 17.55 TWD (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of 6.34 TWD is for.
Which stocks are comparable to Johnson Chemical Pharmaceutical Works Co Ltd?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Johnson Chemical Pharmaceutical Works Co Ltd stock attractive at the current price?
The data as of Nov 10, 2026: price 17.55 TWD, calculated fair value 6.34 TWD (−64%), Quality Score 37/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 4747 calculated?
We run Johnson Chemical Pharmaceutical Works Co Ltd through 24 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 6.34 TWD builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Johnson Chemical Pharmaceutical Works Co Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Johnson Chemical Pharmaceutical Works Co Ltd (4747)?
The closing price on Nov 10, 2026 was 17.55 TWD. Our model-based fair value is 6.34 TWD, about 64% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Johnson Chemical Pharmaceutical Works Co Ltd right now?
The price sits above even our optimistic bull case (7.03 TWD). The favourable scenario is already priced in. Weak quality (37/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. The models converge in a tight band (6.22 TWD to 7.03 TWD), unusually little disagreement for a valuation.
Key figures of Johnson Chemical Pharmaceutical Works Co Ltd
How large is the market capitalisation of Johnson Chemical Pharmaceutical Works Co Ltd (4747)?
The market capitalisation of Johnson Chemical Pharmaceutical Works Co Ltd is 1.6B TWD (≈ $48.6M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Johnson Chemical Pharmaceutical Works Co Ltd (4747)?
The price-to-sales ratio of Johnson Chemical Pharmaceutical Works Co Ltd is 2.76 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Johnson Chemical Pharmaceutical Works Co Ltd (4747)?
Earnings per share at Johnson Chemical Pharmaceutical Works Co Ltd are 0.9700 TWD (price ÷ EPS = P/E 18.1). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Johnson Chemical Pharmaceutical Works Co Ltd (4747)?
The dividend yield of Johnson Chemical Pharmaceutical Works Co Ltd is 3.0% (payout 54.1%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Johnson Chemical Pharmaceutical Works Co Ltd (4747)?
The net margin of Johnson Chemical Pharmaceutical Works Co Ltd is 15.5% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Johnson Chemical Pharmaceutical Works Co Ltd (4747)?
The return on equity (ROE) of Johnson Chemical Pharmaceutical Works Co Ltd is 5.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Johnson Chemical Pharmaceutical Works Co Ltd (4747)?
On an EBIT basis the return on assets of Johnson Chemical Pharmaceutical Works Co Ltd is 5.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Johnson Chemical Pharmaceutical Works Co Ltd (4747)?
The operating margin of Johnson Chemical Pharmaceutical Works Co Ltd is 10.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Johnson Chemical Pharmaceutical Works Co Ltd (4747)?
Revenue at Johnson Chemical Pharmaceutical Works Co Ltd is growing +6.0% versus a year earlier (3y avg +4.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Johnson Chemical Pharmaceutical Works Co Ltd (4747)?
Earnings per share at Johnson Chemical Pharmaceutical Works Co Ltd are growing −46.1% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed
Watch Johnson Chemical Pharmaceutical Works Co Ltd in the live analysis
One click puts Johnson Chemical Pharmaceutical Works Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 10, 2026